LIVIVO - Search results -

Search results

Result 1 - 10 of total 125

Search options

Book ; Online ; E-Book: Advances in crop production and climate change

Yadav, A. S. / Kumar, Narendra / Arora, Sanjay / Srivastava, D. S. / Pant, Hemlata

2021

Abstract: Cover -- Half Title -- Title -- Copyright -- Foreword -- Preface -- Contents -- List of Contributors -- 1. Advances in Rice Production Technologies -- 2. Advances in Wheat and Barley Production Technologies -- 3. Advances in Maize Production Technologies ...

Author's details	A. S. Yadav, Narendra Kumar, Sanjay Arora, D. S. Srivastava, Hemlata Pant
Abstract	Cover -- Half Title -- Title -- Copyright -- Foreword -- Preface -- Contents -- List of Contributors -- 1. Advances in Rice Production Technologies -- 2. Advances in Wheat and Barley Production Technologies -- 3. Advances in Maize Production Technologies -- 4. Improved Technologies for Pearl Millet Cultivation -- 5. Advances in Pulses Production Technologies: A Holistic Approach for New Millennium -- 6. Advances in Oilseeds Production Technologies -- 7. Advance Production Technologies of Sugarcane: A Step Towards Higher Productivity -- 8. Advances in Vegetable Production Technologies -- 9. Advances in Medicinal and Aromatic Crop Production Technologies -- 10. Advances in Forage Crop Production Technologies -- 11. Restoration of Degraded Sodic Lands Through Agroforestry Practices -- 12. Advances in Farm Mechanization in India -- 13. Resource Conservation Techniques for Sustaining Crop Production in Rainfed Foothills Under Changing Climate -- 14. Advances in Reclamation and Management of Salt Affected Soils for Sustainable Crop Production -- 15. Physio-molecular Mechanisms of Drought Tolerance in Crop -- 16. Soil Biodiversity and Its Management for Sustainable Agriculture -- 17. Impact of Climate Change in Crop Protection -- 18. Analysis of Field Experimental Data Using Statistical Calculator.
Keywords	Electronic books
Language	English
Size	1 Online-Ressource (506 Seiten)
Publisher	Taylor & Francis Group
Publishing place	Boca Raton ; London ; New York
Publishing country	United States
Document type	Book ; Online ; E-Book
Note	Description based on publisher supplied metadata and other sources
Remark	Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer ; https://www.livivo.de/getdoc/EBC/7185639
HBZ-ID	HT021725128
ISBN	978-1-00-057252-0 ; 9781032024295 ; 1-00-057252-8 ; 1032024291
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Full text online

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: An Indian Tool for Assessing Appropriateness of Pediatric Hospitalization: Author's Reply.

Arora, Narendra Kumar

Indian pediatrics

2019 Volume 56, Issue 4, Page(s) 334

MeSH term(s)	Child ; Hospitalization ; Humans ; India
Language	English
Publishing date	2019-05-07
Publishing country	India
Document type	Letter ; Comment
ZDB-ID	402594-5
ISSN	0974-7559 ; 0019-6061
ISSN (online)	0974-7559
ISSN	0019-6061
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 859: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Geospatial methodology for determining the regional prevalence of hospital-reported childhood intussusception in patients from India.

Dixit, Shikha / Das, Manoja Kumar / Ramadugu, Durga Chitra / Arora, Narendra Kumar

Scientific reports

2024 Volume 14, Issue 1, Page(s) 6664

Abstract: Both developed and developing countries carry a large burden of pediatric intussusception. Sentinel site surveillance-based studies have highlighted the difference in the regional incidence of intussusception. The objectives of this manuscript were to ... ...

Abstract	Both developed and developing countries carry a large burden of pediatric intussusception. Sentinel site surveillance-based studies have highlighted the difference in the regional incidence of intussusception. The objectives of this manuscript were to geospatially map the locations of hospital-confirmed childhood intussusception cases reported from sentinel hospitals, identify clustering and dispersion, and reveal the potential causes of the underlying pattern. Geospatial analysis revealed positive clustering patterns, i.e., a Moran's I of 0.071 at a statistically significant (p value < 0.0010) Z score of 16.14 for the intussusception cases across India (cases mapped n = 2221), with 14 hotspots in two states (Kerala = 6 and Tamil Nadu = 8) at the 95% CI. Granular analysis indicated that 67% of the reported cases resided < 50 km from the sentinel hospitals, and the average travel distance to the sentinel hospital from the patient residence was calculated as 47 km (CI 95% min 1 km-max 378 km). Easy access and facility referral preferences were identified as the main causes of the existing clustering pattern of the disease. We recommend designing community-based surveillance studies to improve the understanding of the prevalence and regional epidemiological burden of the disease.
MeSH term(s)	Humans ; Child ; India/epidemiology ; Intussusception/epidemiology ; Intussusception/etiology ; Prevalence ; Hospitals ; Sentinel Surveillance
Language	English
Publishing date	2024-03-20
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-024-57187-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: INCLEN - BMGF Research Program to Emphasize Context Sensitive Approaches for Addressing the Challenges of Childhood Pneumonia in India.

Das, Manoja Kumar / Arora, Narendra Kumar

Indian pediatrics

2021 Volume 58, Issue 11, Page(s) 1017–1018

MeSH term(s)	Child ; Child Health ; Humans ; India/epidemiology ; Pneumonia/epidemiology
Language	English
Publishing date	2021-11-27
Publishing country	India
Document type	Journal Article
ZDB-ID	402594-5
ISSN	0974-7559 ; 0019-6061
ISSN (online)	0974-7559
ISSN	0019-6061
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 859: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: COVID-19 vaccine development and the way forward.

Arora, Narendra Kumar / Das, Manoja Kumar

Indian journal of public health

2020 Volume 64, Issue Supplement, Page(s) S108–S111

Abstract: The whole globe is reeling under the COVID-19 pandemic now. With the scale and severity of infection, number of deaths and lack of any definite therapeutic armamentarium, the vaccine development has been accelerated at a never-before pace. A wide variety ...

Abstract	The whole globe is reeling under the COVID-19 pandemic now. With the scale and severity of infection, number of deaths and lack of any definite therapeutic armamentarium, the vaccine development has been accelerated at a never-before pace. A wide variety of vaccine technologies and platforms are being attempted. Out of the over 108 efforts, 100 are in preclinical and eight in Phase 1 or 2 trial stage. While the availability of newer technologies has facilitated development, there are several challenges on the way including limited understanding of the pathophysiology, targeting humoral or mucosal immunity, lack of suitable animal model, poor success of human severe acute respiratory syndrome/Middle East Respiratory Syndrome vaccines, limited efficacy of influenza vaccines, and immune exaggeration with animal coronavirus vaccines. With the current scenario with political, funding, research, and regulatory supports, if everything sails through smoothly, the successful vaccine is expected in 12-18 months. Modestly efficacious vaccine may be also a good achievement.
MeSH term(s)	Antiviral Agents/therapeutic use ; Betacoronavirus ; Biomedical Research/organization & administration ; COVID-19 ; COVID-19 Vaccines ; Coronavirus Infections/drug therapy ; Coronavirus Infections/economics ; Coronavirus Infections/epidemiology ; Coronavirus Infections/immunology ; Coronavirus Infections/prevention & control ; Humans ; India/epidemiology ; Inflammation Mediators/metabolism ; Pandemics/prevention & control ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/prevention & control ; SARS-CoV-2 ; Time Factors ; Viral Vaccines/administration & dosage ; Viral Vaccines/economics ; Viral Vaccines/immunology ; Viral Vaccines/supply & distribution
Chemical Substances	Antiviral Agents ; COVID-19 Vaccines ; Inflammation Mediators ; Viral Vaccines
Keywords	covid19
Language	English
Publishing date	2020-06-10
Publishing country	India
Document type	Journal Article
ZDB-ID	800737-8
ISSN	2229-7693 ; 0019-557X
ISSN (online)	2229-7693
ISSN	0019-557X
DOI	10.4103/ijph.IJPH_520_20
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 760: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COVID-19 vaccine development and the way forward

Narendra Kumar Arora / Manoja Kumar Das

Indian Journal of Public Health, Vol 64, Iss 6, Pp 108-

2020 Volume 111

Abstract	The whole globe is reeling under the COVID-19 pandemic now. With the scale and severity of infection, number of deaths and lack of any definite therapeutic armamentarium, the vaccine development has been accelerated at a never-before pace. A wide variety of vaccine technologies and platforms are being attempted. Out of the over 108 efforts, 100 are in preclinical and eight in Phase 1 or 2 trial stage. While the availability of newer technologies has facilitated development, there are several challenges on the way including limited understanding of the pathophysiology, targeting humoral or mucosal immunity, lack of suitable animal model, poor success of human severe acute respiratory syndrome/Middle East Respiratory Syndrome vaccines, limited efficacy of influenza vaccines, and immune exaggeration with animal coronavirus vaccines. With the current scenario with political, funding, research, and regulatory supports, if everything sails through smoothly, the successful vaccine is expected in 12–18 months. Modestly efficacious vaccine may be also a good achievement.
Keywords	coronavirus ; covid-19 ; severe acute respiratory syndrome-cov-2 ; technologies ; vaccines development ; Public aspects of medicine ; RA1-1270 ; covid19
Language	English
Publishing date	2020-01-01T00:00:00Z
Publisher	Wolters Kluwer Medknow Publications
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Blood Biomarkers in Alzheimer's Disease.

Mandal, Pravat K / Maroon, Joseph C / Garg, Arun / Arora, Narendra Kumar / Bansal, Rishu / Kaushik, Aditi / Samkaria, Avantika / Kumaran, Gayathri / Arora, Yashika

ACS chemical neuroscience

2023 Volume 14, Issue 22, Page(s) 3975–3978

Abstract: Alzheimer's disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide. The characteristic pathological manifestation of AD includes the deposition of extracellular insoluble β amyloid plaques and intracellular ... ...

Abstract	Alzheimer's disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide. The characteristic pathological manifestation of AD includes the deposition of extracellular insoluble β amyloid plaques and intracellular neurofibrillary tangles formed from hyperphosphorylated tau protein. Cost effective and minimally invasive peripheral blood-based biomarkers are critical for early AD diagnosis. Currently, the plasma based two fraction of β amyloid peptide ratio (Aβ42/40) and phosphorylated tau (p-tau) are considered as blood-based biomarkers for AD diagnosis. Recent research indicates that oxidative stress (OS) occurs prior to amyloid plaque (Aβ) formation and abnormal tau phosphorylation in AD. The imbalance of the master antioxidant, glutathione (GSH), and prooxidants (iron, zinc, and copper)─plays a crucial role in AD neurodegeneration. We present peripheral blood-based OS related biomarkers that are mechanistically involved in the disease process and may serve as a novel screening tool for early detection of AD onset. This OS based approach may also provide a quick and cost efficient method to monitor the effects of disease-modifying therapies in AD clinical trials.
MeSH term(s)	Humans ; Alzheimer Disease/metabolism ; tau Proteins/metabolism ; Amyloid beta-Peptides/metabolism ; Neurofibrillary Tangles/metabolism ; Biomarkers
Chemical Substances	tau Proteins ; Amyloid beta-Peptides ; Biomarkers
Language	English
Publishing date	2023-10-25
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1948-7193
ISSN (online)	1948-7193
DOI	10.1021/acschemneuro.3c00641
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: COVID-19 vaccine development and the way forward

Arora, Narendra Kumar / Das, Manoja Kumar

Indian J Public Health

Abstract	The whole globe is reeling under the COVID-19 pandemic now. With the scale and severity of infection, number of deaths and lack of any definite therapeutic armamentarium, the vaccine development has been accelerated at a never-before pace. A wide variety of vaccine technologies and platforms are being attempted. Out of the over 108 efforts, 100 are in preclinical and eight in Phase 1 or 2 trial stage. While the availability of newer technologies has facilitated development, there are several challenges on the way including limited understanding of the pathophysiology, targeting humoral or mucosal immunity, lack of suitable animal model, poor success of human severe acute respiratory syndrome/Middle East Respiratory Syndrome vaccines, limited efficacy of influenza vaccines, and immune exaggeration with animal coronavirus vaccines. With the current scenario with political, funding, research, and regulatory supports, if everything sails through smoothly, the successful vaccine is expected in 12-18 months. Modestly efficacious vaccine may be also a good achievement.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #32496238
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Assessment of MMP14, CAV2, CLU and SPARCL1 expression profiles in endometriosis.

Pant, Anuja / Dakal, Tikam Chand / Moar, Kareena / Dhabhai, Bhanupriya / Arora, Taruna K / Sharma, Narendra Kumar / Ranga, Vipin / Maurya, Pawan Kumar

Pathology, research and practice

2023 Volume 251, Page(s) 154892

Abstract: Endometriotic cells exhibit a notable degree of invasiveness and some characteristics of tissue remodeling underlying lesion formation. In this regard, do matrix metalloproteinases 14 (MMP14) and other related genes such as SPARC-like protein 1 (SPARCL1), ...

Abstract	Endometriotic cells exhibit a notable degree of invasiveness and some characteristics of tissue remodeling underlying lesion formation. In this regard, do matrix metalloproteinases 14 (MMP14) and other related genes such as SPARC-like protein 1 (SPARCL1), caveolin 2 (CAV2), and clusterin (CLU) exert any significant influence in the processes of endometriosis development and pathophysiology is not apparent. We aim to assess whether these genes could serve as potential diagnostic biomarkers in endometriosis. Microarray-based gene expression analysis was performed on total RNA extracted from endometriotic tissue samples treated with and without gonadotropin-releasing hormone agonist (GnRHa). The GnRHa untreated patients were considered the control group. The validation of genes was performed using quantitative real-time polymerase chain reaction (qRT-PCR). qRT-PCR analysis showed significant downregulation in the expression of MMP14 (p = 0.024), CAV2 (p = 0.017), and upregulation of CLU (p = 0.005) in endometriosis patients treated with GnRHa. SPARCL1 did not show any significant (p = 0.30) change in the expression compared to the control group. These data have the potential to contribute to the comprehension of the molecular pathways implicated in the remodeling of the extracellular matrix, which is a vital step for the physiology of the endometrium. Based on the result, it is concluded that changes in the expression of MMP14, CAV2, and CLU post-treatment imply their role in the pathophysiology of endometriosis and may serve as a potential diagnostic biomarker of endometriosis in response to GnRHa treatment in patients with ovarian endometrioma.
MeSH term(s)	Female ; Humans ; Endometriosis/pathology ; Clusterin/genetics ; Clusterin/metabolism ; Caveolin 2/metabolism ; Matrix Metalloproteinase 14/genetics ; Matrix Metalloproteinase 14/metabolism ; Endometrium/pathology ; Calcium-Binding Proteins/metabolism ; Extracellular Matrix Proteins/genetics
Chemical Substances	Clusterin ; Caveolin 2 ; Matrix Metalloproteinase 14 (EC 3.4.24.80) ; MMP14 protein, human (EC 3.4.24.80) ; CLU protein, human ; SPARCL1 protein, human ; Calcium-Binding Proteins ; Extracellular Matrix Proteins
Language	English
Publishing date	2023-10-14
Publishing country	Germany
Document type	Journal Article
ZDB-ID	391889-0
ISSN	1618-0631 ; 0344-0338
ISSN (online)	1618-0631
ISSN	0344-0338
DOI	10.1016/j.prp.2023.154892
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud III Zs.20: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial.

Reddy, Naveen / Reddy, Pramod / Ranpura, Ankit / Maharaj, Narendra / Arora, Rajendersingh / Mamillapalli, Gopichand / Adhav, Aditya Shirish / Diwan, Ashok Kumar / Manikhas, Alexey / Krasnozhon, Dmitriy

JCO global oncology

2024 Volume 10, Page(s) e2200328

Abstract: Purpose: Dr Reddy's Laboratories Trastuzumab (DRL_TZ) is a biosimilar to Herceptin under development. The present study was conducted to evaluate efficacy, safety, pharmacokinetics (PKs), and immunogenicity of DRL_TZ in comparison with the reference ... ...

Abstract	Purpose: Dr Reddy's Laboratories Trastuzumab (DRL_TZ) is a biosimilar to Herceptin under development. The present study was conducted to evaluate efficacy, safety, pharmacokinetics (PKs), and immunogenicity of DRL_TZ in comparison with the reference medicinal product (RMP) along with concomitant weekly paclitaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Methods: This was a randomized, double-blind study in female patients with HER2-positive MBC, randomly assigned in a 1:1 ratio to receive either DRL_TZ or the RMP, that is, an innovator product sourced from the European region, along with additional chemotherapy, as first-line treatment for up to 24 weeks. The primary end point was the best overall response rate (ORR) as per RECIST 1.1 criteria. Progression-free survival rate at 6 months (PFS6), safety, immunogenicity, and PK parameters were assessed as secondary end points. Results: A total of 164 patients were randomly assigned to receive either DRL_TZ or the RMP. Best ORR in the per-protocol population was comparable, 91.9% (93.3% CI, 83.2 to 96.3) versus 82.1% (93.3% CI, 72.0 to 89.1) in DRL_TZ and RMP arms, respectively; the difference between the arms was 9.8% with a 93.3% CI of -1.3 to 20.8. The PFS6 rate, safety, PK profile, and antidrug antibody incidence were comparable. An additional 44 patients were recruited in the postrandomization phase, in an open-label manner, and started on DRL_TZ to generate more data on efficacy, safety, and immunogenicity. The additional data with DRL_TZ, when pooled, were similar to the RMP data. Conclusion: DRL_TZ was found to have similar efficacy and comparable safety, PK, and immunogenicity profiles as the RMP.
MeSH term(s)	Humans ; Female ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Trastuzumab/adverse effects ; Receptor, ErbB-2 ; Paclitaxel/therapeutic use
Chemical Substances	Trastuzumab (P188ANX8CK) ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Paclitaxel (P88XT4IS4D)
Language	English
Publishing date	2024-01-18
Publishing country	United States
Document type	Randomized Controlled Trial ; Journal Article
ISSN	2687-8941
ISSN (online)	2687-8941
DOI	10.1200/GO.22.00328
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED